{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:11:26Z","timestamp":1787019086669,"version":"build-2736575974"},"reference-count":12,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The combination nivolumab-relatlimab has demonstrated therapeutic benefits for patients with metastatic melanoma. However, its adverse effects can affect various organs, including the eye.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>\n                      We present the case of an 80-year-old man who developed complete color blindness after the 2\n                      <jats:sup>nd<\/jats:sup>\n                      dose of nivolumab-relatlimab for advanced cutaneous melanoma. He also had significant blurry vision. Fundoscopy identified bilateral serous macular detachment. Ocular coherence tomography confirmed serous infiltration within the macula. After a thorough investigation, causality assessment linked this retinal effect to nivolumab-relatlimab (probable relationship via Naranjo criteria).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcome<\/jats:title>\n                    <jats:p>The patient was treated with corticosteroids, intravenous immunoglobulin (IVIG), rituximab, and plasmapheresis, with improvement in blurry vision. However, he continued to experience persistent absence of color perception (\u201cblack and white vision\u201d) at a follow-up visit six months later.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion\/conclusion<\/jats:title>\n                    <jats:p>Further studies are necessary to understand the exact pathophysiology of this process. We hypothesize that it involves direct toxicity to the photoreceptors or retinal ganglion cells, leading to irreversible color vision loss. Effective strategies for preventing this significant, life-changing toxic effect of nivolumab-relatlimab should be sought.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251340014","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T03:51:53Z","timestamp":1747108313000},"page":"1014-1017","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Complete color vision loss in a patient with metastatic melanoma of the skin treated with nivolumab-relatlimab"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9508-9911","authenticated-orcid":false,"given":"Ruba","family":"Alchaikh Hassan","sequence":"first","affiliation":[{"name":"Eisenhower Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderson","family":"Vu","sequence":"additional","affiliation":[{"name":"Eisenhower Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Tsai","sequence":"additional","affiliation":[{"name":"Eisenhower Health"},{"name":"Department of Medical Oncology and Hematology, University of California in San Diego Health System, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0425-8394","authenticated-orcid":false,"given":"Constantin A","family":"Dasanu","sequence":"additional","affiliation":[{"name":"Eisenhower Health"},{"name":"Department of Medical Oncology and Hematology, University of California in San Diego Health System, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01136"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109970"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2022.04.19"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2022.1044904"},{"key":"e_1_3_2_7_2","first-page":"1063","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic Side effects","volume":"38","author":"Dalvin LA","unstructured":"Dalvin LA, Shields CL, Orloff M, et al. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic Side effects. Retina 2018; 38: 1063\u20131078.","journal-title":"Retina 2018"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2147\/EB.S277760"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002119"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/01658107.2020.1797824"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/0145482X1611000608"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000000217"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.911"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251340014","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251340014","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251340014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:31:08Z","timestamp":1777689068000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251340014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":12,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/10781552251340014"],"URL":"https:\/\/doi.org\/10.1177\/10781552251340014","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]}}}